CY1122419T1 - Εξανθρωπισμενοι ποντικοι οι οποιοι εκφραζουν βαριες αλυσιδες που περιεχουν τομεις vl - Google Patents
Εξανθρωπισμενοι ποντικοι οι οποιοι εκφραζουν βαριες αλυσιδες που περιεχουν τομεις vlInfo
- Publication number
- CY1122419T1 CY1122419T1 CY20191101302T CY191101302T CY1122419T1 CY 1122419 T1 CY1122419 T1 CY 1122419T1 CY 20191101302 T CY20191101302 T CY 20191101302T CY 191101302 T CY191101302 T CY 191101302T CY 1122419 T1 CY1122419 T1 CY 1122419T1
- Authority
- CY
- Cyprus
- Prior art keywords
- heavy chain
- human
- light chain
- human immunoglobulin
- dehumanized
- Prior art date
Links
- 241000699670 Mus sp. Species 0.000 title 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 abstract 3
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 abstract 2
- 241001465754 Metazoa Species 0.000 abstract 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 abstract 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 abstract 1
- 241000283984 Rodentia Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24046—Adamalysin (3.4.24.46)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Environmental Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Steroid Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Housing For Livestock And Birds (AREA)
- Central Heating Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261593463P | 2012-02-01 | 2012-02-01 | |
| US201261677538P | 2012-07-31 | 2012-07-31 | |
| PCT/US2013/024295 WO2013116609A1 (en) | 2012-02-01 | 2013-02-01 | Humanized rodents that express heavy chains containing vl domains |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122419T1 true CY1122419T1 (el) | 2021-01-27 |
Family
ID=47714588
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101302T CY1122419T1 (el) | 2012-02-01 | 2019-12-10 | Εξανθρωπισμενοι ποντικοι οι οποιοι εκφραζουν βαριες αλυσιδες που περιεχουν τομεις vl |
| CY20211100659T CY1124361T1 (el) | 2012-02-01 | 2021-07-20 | Εξανθρωπισμενα τρωκτικα που εκφραζουν βαριες αλυσιδες που περιεχουν τομεις vl |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211100659T CY1124361T1 (el) | 2012-02-01 | 2021-07-20 | Εξανθρωπισμενα τρωκτικα που εκφραζουν βαριες αλυσιδες που περιεχουν τομεις vl |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US20130212719A1 (enExample) |
| EP (3) | EP3597038B1 (enExample) |
| JP (6) | JP2015505477A (enExample) |
| KR (2) | KR20190006029A (enExample) |
| CN (2) | CN104202971B (enExample) |
| AU (3) | AU2013204758B2 (enExample) |
| BR (1) | BR112014018843B1 (enExample) |
| CA (1) | CA2863175A1 (enExample) |
| CY (2) | CY1122419T1 (enExample) |
| DK (2) | DK3597038T3 (enExample) |
| ES (2) | ES2753774T3 (enExample) |
| HR (2) | HRP20192218T1 (enExample) |
| HU (2) | HUE055610T2 (enExample) |
| IL (3) | IL233827A0 (enExample) |
| LT (2) | LT3597038T (enExample) |
| ME (1) | ME03611B (enExample) |
| MX (2) | MX2020003491A (enExample) |
| NZ (5) | NZ793447A (enExample) |
| PL (2) | PL3597038T3 (enExample) |
| PT (2) | PT2809150T (enExample) |
| RS (2) | RS62023B1 (enExample) |
| RU (2) | RU2770016C2 (enExample) |
| SG (3) | SG10201606256TA (enExample) |
| SI (2) | SI3597038T1 (enExample) |
| SM (2) | SMT202100401T1 (enExample) |
| WO (1) | WO2013116609A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2669298A3 (en) * | 2008-05-23 | 2014-02-26 | Ablexis, LLC | Single variable immunoglobulin domain comprising VL-DH-JL |
| PT2564695E (pt) | 2009-07-08 | 2015-06-03 | Kymab Ltd | Modelos animais e moléculas terapêuticas |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| RU2612903C2 (ru) | 2010-08-02 | 2017-03-13 | Ридженерон Фармасьютикалз, Инк. | Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены |
| RS66089B1 (sr) | 2011-08-05 | 2024-11-29 | Regeneron Pharma | Humanizovani miševi univerzalnog lakog lanca |
| EP3839049A3 (en) | 2011-09-19 | 2021-10-20 | Kymab Limited | Antibodies, variable domains & chains tailored for human use |
| EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| GB201122047D0 (en) * | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| SI2793567T1 (sl) | 2011-12-20 | 2019-05-31 | Regeneron Pharmaceuticals, Inc. | Humanizirane lahkoverižne miši |
| HRP20192218T1 (hr) * | 2012-02-01 | 2020-03-06 | Regeneron Pharmaceuticals, Inc. | Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| JP2015519076A (ja) | 2012-06-12 | 2015-07-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 限定された免疫グロブリン重鎖遺伝子座を有するヒト化非ヒト動物 |
| CN105734081A (zh) | 2013-02-20 | 2016-07-06 | 瑞泽恩制药公司 | 具有修饰的免疫球蛋白重链序列的非人类动物 |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| ES2993142T3 (en) | 2013-10-01 | 2024-12-23 | Kymab Ltd | Animal models and therapeutic molecules |
| EP3895528A1 (en) | 2014-03-21 | 2021-10-20 | Regeneron Pharmaceuticals, Inc. | Non-human animals that make single domain binding proteins |
| CN106164092A (zh) | 2014-03-21 | 2016-11-23 | 瑞泽恩制药公司 | 表现不同结合特征的vl抗原结合蛋白 |
| JP2018508224A (ja) * | 2015-03-19 | 2018-03-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗原を結合する軽鎖可変領域を選択する非ヒト動物 |
| EP4335918A3 (en) * | 2015-04-03 | 2024-04-17 | Dana-Farber Cancer Institute, Inc. | Composition and methods of genome editing of b-cells |
| CN109072191B (zh) * | 2016-04-04 | 2024-03-22 | 苏黎世联邦理工学院 | 用于蛋白生产和文库产生的哺乳动物细胞系 |
| CN109475109B (zh) | 2016-05-20 | 2021-10-29 | 瑞泽恩制药公司 | 用于使用多个引导rna来破坏免疫耐受性的方法 |
| CN110719732B (zh) * | 2017-03-30 | 2022-11-18 | 犹他州立大学 | 表达蜘蛛丝的转基因蚕 |
| PL4140297T3 (pl) * | 2017-12-05 | 2025-08-25 | Regeneron Pharmaceuticals, Inc. | Myszy mające zmodyfikowany sposobami inżynierii łańcuch lekki lambda immunoglobuliny i ich zastosowania |
| US20210051929A1 (en) * | 2018-03-24 | 2021-02-25 | Regeneron Pharmaceuticals, Inc. | Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
| IL318469A (en) * | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of reorganizing transgenic DH-DH, and their uses |
| JP2023540808A (ja) | 2020-09-11 | 2023-09-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗原特異的抗体の同定及び産生 |
| WO2022132943A1 (en) | 2020-12-16 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
| CN114645042A (zh) * | 2020-12-18 | 2022-06-21 | 中国食品药品检定研究院 | 一种构建具有表达荧光素酶和红色荧光蛋白的重组巨噬细胞的转基因小鼠的方法 |
| CN114196626A (zh) * | 2022-02-16 | 2022-03-18 | 北京国卫生物科技有限公司 | 脐带间充质干细胞及其分离培养扩增方法 |
| CN118339300A (zh) * | 2024-01-02 | 2024-07-12 | 江苏集萃药康生物科技股份有限公司 | 产生人源化抗体的动物模型及其构建方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6774279B2 (en) | 1997-05-30 | 2004-08-10 | Carnegie Institution Of Washington | Use of FLP recombinase in mice |
| CA2422155A1 (en) * | 2000-08-03 | 2002-02-14 | Wim Van Schooten | Production of humanized antibodies in transgenic animals |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| CN101016543A (zh) * | 2000-11-17 | 2007-08-15 | 罗切斯特大学 | 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法 |
| US7473557B2 (en) | 2001-06-06 | 2009-01-06 | Regeneron Pharmaceuticals, Inc. | Method for targeting transcriptionally active loci |
| EP1458852B1 (en) | 2001-12-21 | 2011-03-09 | ThromboGenics N.V. | Compositions for the in vitro derivation and culture of embryonic stem (es) cell lines with germline transmission capability and for the culture of adult stem cells |
| WO2003081993A2 (en) * | 2002-03-22 | 2003-10-09 | Origen Therapeutics | Transgenic aves producing human polyclonal antibodies |
| EP1644417B1 (en) * | 2003-07-15 | 2014-04-30 | Therapeutic Human Polyclonals, Inc. | Humanized immunoglobulin loci |
| DK2767161T3 (en) | 2004-10-19 | 2018-05-07 | Regeneron Pharma | Method of generating an animal homozygous for genetic modification |
| WO2006047367A2 (en) * | 2004-10-22 | 2006-05-04 | Therapeutic Human Polyclonals, Inc. | Suppression of endogenous immunoglubolin expression in non-human transgenic animals |
| JP5514539B2 (ja) * | 2006-03-31 | 2014-06-04 | メダレックス・リミテッド・ライアビリティ・カンパニー | ヒト抗体の調製に用いるためのキメラ抗体を発現するトランスジェニック動物 |
| ATE536374T1 (de) * | 2006-09-01 | 2011-12-15 | Therapeutic Human Polyclonals Inc | Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren |
| US8426565B2 (en) * | 2007-08-30 | 2013-04-23 | Walter And Eliza Hall Institute Of Medical Research | Dendritic cell marker and uses thereof |
| TWI464262B (zh) * | 2007-09-26 | 2014-12-11 | 中外製藥股份有限公司 | 抗體固定區的變異 |
| US7659842B2 (en) | 2007-10-24 | 2010-02-09 | Infineon Technologies Ag | Quantization error reduction in PWM full-MASH converters |
| EP2669298A3 (en) * | 2008-05-23 | 2014-02-26 | Ablexis, LLC | Single variable immunoglobulin domain comprising VL-DH-JL |
| HUE057994T2 (hu) * | 2008-06-27 | 2022-06-28 | Merus Nv | Antitesttermelõ, transzgenikus, egérfélékhez tartozó állat |
| AU2009287165A1 (en) * | 2008-08-29 | 2010-03-04 | Symphogen A/S | Method for cloning avian-derived antibodies |
| WO2010091182A2 (en) * | 2009-02-04 | 2010-08-12 | Molecular Innovations | Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein |
| PT2564695E (pt) * | 2009-07-08 | 2015-06-03 | Kymab Ltd | Modelos animais e moléculas terapêuticas |
| RU2425880C2 (ru) * | 2009-07-30 | 2011-08-10 | Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН | Способ получения трансгенных мышей |
| CN103228130B (zh) * | 2010-06-17 | 2016-03-16 | 科马布有限公司 | 动物模型及治疗分子 |
| RU2612903C2 (ru) * | 2010-08-02 | 2017-03-13 | Ридженерон Фармасьютикалз, Инк. | Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены |
| PL4067496T3 (pl) * | 2011-02-25 | 2023-07-31 | Regeneron Pharmaceuticals, Inc. | Myszy adam6 |
| RS66089B1 (sr) * | 2011-08-05 | 2024-11-29 | Regeneron Pharma | Humanizovani miševi univerzalnog lakog lanca |
| SI2793567T1 (sl) * | 2011-12-20 | 2019-05-31 | Regeneron Pharmaceuticals, Inc. | Humanizirane lahkoverižne miši |
| HRP20192218T1 (hr) * | 2012-02-01 | 2020-03-06 | Regeneron Pharmaceuticals, Inc. | Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene |
| JP2015519076A (ja) * | 2012-06-12 | 2015-07-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 限定された免疫グロブリン重鎖遺伝子座を有するヒト化非ヒト動物 |
| SMT202000558T1 (it) * | 2016-11-04 | 2020-11-10 | Regeneron Pharma | Animali non umani aventi un locus di catena leggera di immunoglobulina lambda ingegnerizzata |
-
2013
- 2013-02-01 HR HRP20192218TT patent/HRP20192218T1/hr unknown
- 2013-02-01 US US13/756,889 patent/US20130212719A1/en not_active Abandoned
- 2013-02-01 SG SG10201606256TA patent/SG10201606256TA/en unknown
- 2013-02-01 SG SG10201913428QA patent/SG10201913428QA/en unknown
- 2013-02-01 KR KR1020187037872A patent/KR20190006029A/ko not_active Ceased
- 2013-02-01 NZ NZ793447A patent/NZ793447A/en unknown
- 2013-02-01 LT LTEP19191081.9T patent/LT3597038T/lt unknown
- 2013-02-01 EP EP19191081.9A patent/EP3597038B1/en active Active
- 2013-02-01 HU HUE19191081A patent/HUE055610T2/hu unknown
- 2013-02-01 RU RU2018122695A patent/RU2770016C2/ru active
- 2013-02-01 JP JP2014555736A patent/JP2015505477A/ja not_active Withdrawn
- 2013-02-01 WO PCT/US2013/024295 patent/WO2013116609A1/en not_active Ceased
- 2013-02-01 CN CN201380017544.2A patent/CN104202971B/zh active Active
- 2013-02-01 CN CN201610371631.3A patent/CN106117364B/zh active Active
- 2013-02-01 NZ NZ734504A patent/NZ734504A/en unknown
- 2013-02-01 DK DK19191081.9T patent/DK3597038T3/da active
- 2013-02-01 RU RU2014133653A patent/RU2664185C2/ru active
- 2013-02-01 ME MEP-2019-348A patent/ME03611B/me unknown
- 2013-02-01 SG SG11201404477YA patent/SG11201404477YA/en unknown
- 2013-02-01 DK DK13704329T patent/DK2809150T3/da active
- 2013-02-01 NZ NZ810648A patent/NZ810648A/en unknown
- 2013-02-01 NZ NZ719228A patent/NZ719228A/en unknown
- 2013-02-01 SM SM20210401T patent/SMT202100401T1/it unknown
- 2013-02-01 ES ES13704329T patent/ES2753774T3/es active Active
- 2013-02-01 EP EP21167681.2A patent/EP3912465A1/en active Pending
- 2013-02-01 MX MX2020003491A patent/MX2020003491A/es unknown
- 2013-02-01 SI SI201331882T patent/SI3597038T1/sl unknown
- 2013-02-01 SI SI201331592T patent/SI2809150T1/sl unknown
- 2013-02-01 ES ES19191081T patent/ES2870703T3/es active Active
- 2013-02-01 PT PT137043295T patent/PT2809150T/pt unknown
- 2013-02-01 SM SM20190685T patent/SMT201900685T1/it unknown
- 2013-02-01 RS RS20210791A patent/RS62023B1/sr unknown
- 2013-02-01 EP EP13704329.5A patent/EP2809150B1/en active Active
- 2013-02-01 CA CA2863175A patent/CA2863175A1/en active Pending
- 2013-02-01 AU AU2013204758A patent/AU2013204758B2/en active Active
- 2013-02-01 NZ NZ627977A patent/NZ627977A/en active IP Right Revival
- 2013-02-01 PT PT191910819T patent/PT3597038T/pt unknown
- 2013-02-01 LT LT13704329T patent/LT2809150T/lt unknown
- 2013-02-01 PL PL19191081T patent/PL3597038T3/pl unknown
- 2013-02-01 MX MX2019002517A patent/MX373286B/es active IP Right Grant
- 2013-02-01 BR BR112014018843-2A patent/BR112014018843B1/pt active IP Right Grant
- 2013-02-01 KR KR1020147024417A patent/KR20140123983A/ko not_active Ceased
- 2013-02-01 HU HUE13704329A patent/HUE046744T2/hu unknown
- 2013-02-01 PL PL13704329T patent/PL2809150T3/pl unknown
- 2013-02-01 RS RS20191615A patent/RS59699B1/sr unknown
-
2014
- 2014-07-27 IL IL233827A patent/IL233827A0/en active IP Right Grant
-
2015
- 2015-10-23 AU AU2015246154A patent/AU2015246154B2/en active Active
-
2016
- 2016-10-14 US US15/294,488 patent/US20170094955A1/en not_active Abandoned
-
2017
- 2017-10-27 AU AU2017251848A patent/AU2017251848B2/en active Active
-
2018
- 2018-02-09 JP JP2018022012A patent/JP6698718B2/ja active Active
- 2018-08-21 IL IL261280A patent/IL261280B/en active IP Right Grant
-
2019
- 2019-07-12 JP JP2019130027A patent/JP6942757B2/ja active Active
- 2019-08-13 IL IL268675A patent/IL268675B/en active IP Right Grant
- 2019-12-10 CY CY20191101302T patent/CY1122419T1/el unknown
-
2021
- 2021-04-07 US US17/224,524 patent/US20210368751A1/en not_active Abandoned
- 2021-06-15 JP JP2021099420A patent/JP7187615B2/ja active Active
- 2021-06-23 HR HRP20210987TT patent/HRP20210987T1/hr unknown
- 2021-07-20 CY CY20211100659T patent/CY1124361T1/el unknown
-
2022
- 2022-11-30 JP JP2022191963A patent/JP7525579B2/ja active Active
-
2023
- 2023-10-05 JP JP2023173593A patent/JP2023168590A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122419T1 (el) | Εξανθρωπισμενοι ποντικοι οι οποιοι εκφραζουν βαριες αλυσιδες που περιεχουν τομεις vl | |
| CY1121638T1 (el) | Ποντικοι με εξανθρωπισμενη ελαφρια αλυσιδα | |
| CY1124320T1 (el) | Ανθρωποποιημενα μη ανθρωπινα ζωα με περιορισμενους τοπους βαριας αλυσιδας ανοσοσφαιρινης | |
| CY1122091T1 (el) | Μορια δεσμευσης-cd37 και ανοσοσυζευγματα εξ αυτων | |
| CY1121608T1 (el) | Ποντικια που δημιουργουν αντισωματα βαριας αλυσιδας | |
| CY1122940T1 (el) | Μη ανθρωπινα ζωα που εχουν ενα εξανθρωπισμενο γονιδιο προγραμματισμενου κυτταρικου θανατου 1 | |
| CY1122205T1 (el) | Ποντικοι adam6 | |
| CY1122409T1 (el) | Σχεδιασμος σταθερου ετεροδιμερικου αντισωματος με μεταλαξεις στην επικρατεια fc | |
| CY1119071T1 (el) | Εξανθρωποποιημενα il-7 τρωκτικα | |
| CY1121864T1 (el) | Τρωκτικα που εκφραζουν ευαισθητες στο ρη αλληλουχιες ανοσοσφαιρινης | |
| CY1123215T1 (el) | Πολυνουκλεοτιδια τα οποια κωδικοποιουν αντισωματα τρωκτικων με ανθρωπινους ιδιοτυπους και ζωα τα οποια διαθετουν αυτα | |
| CY1121979T1 (el) | Ποντικια που εκφραζουν ανθρωποποιημενους τ-λεμφοκυτταρικους συνυποδοχεις | |
| IL280004A (en) | Antibody molecules that bind pd-l1 and cd137 | |
| CY1121410T1 (el) | Μη-ανθρωπινα ζωα που εχουν ενα εξανθρωποποιημενο γονιδιο ρυθμιστικης πρωτεϊνης σηματος | |
| CY1118241T1 (el) | Ποντικος κοινης ελαφριας αλυσου | |
| CY1124108T1 (el) | Μορια συνδεσης που αναστελουν την αναπτυξη καρκινου | |
| CY1121545T1 (el) | Ποντικοι που εκφραζουν περιορισμενο ρεπερτοριο ελαφριων αλυσιδων ανοσοσφαιρινης | |
| CY1118923T1 (el) | ΔΡΑΣΤΙΚΑ ΜΕΤΑΛΛΑΓΜΑΤΑ Fc ΑΝΤΙΣΩΜΑΤΟΣ ΑΝΘΕΚΤΙΚΑ ΣΕ ΠΡΩΤΕΑΣΕΣ | |
| CY1119691T1 (el) | Παραγοντες συνδεσης cd33 | |
| MY165287A (en) | Mice expressing a light chain with human lambda variable and mouse constant regions | |
| EP2995682A4 (en) | NUCLEIC ACID OF CODED CHIMERIC GPC3 ANTIGEN RECEPTOR PROTEIN AND T-LYMPHOCYTES EXPRESSIVE CHIMERIC GPC3 ANTIGEN RECEPTOR PROTEIN | |
| CY1112739T1 (el) | Αντισωματα και ανοσοσυζευγματα αντι-cd79β και μεθοδοι χρησης | |
| EP3538135A4 (en) | POLYTHERAPIES OF PREDNISONE AND URICASE MOLECULES AND THEIR USES | |
| EP3954706A4 (en) | Antibody to programmed cell death protein ligand-1 (pd-l1), and use thereof | |
| MX363022B (es) | Roedores humanizados que expresan cadenas pesadas que contienen dominios vl. |